You are here

Perspective on optimal design in pharmacometrics is now published in CPT:PSP

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe’s European Federation of Pharmaceutical Industries and Associations Members. F Mentré, M Chenel, E Comets, J Grevel, A Hooker, MO Karlsson, M Lavielle and I Gueorguieva. CPT: Pharmacometrics & Systems Pharmacology 2013, 2, e46 Abstract Methods and software tools for optimal design in nonlinear mixed effect models, based on the Fisher information matrix, have been developed for a decade. Academic groups regularly proposed new versions. Present tools do not incorporate adaptive designs for these models although prior information is needed and adaptive designs are increasingly used in drug development. We conducted a study among drug companies of the Drug and Disease Model Resources consortium to identify current practices and expectations. 

Work package: 
News category: 

Associated members

Academia
Andrew Hooker's picture
Andrew Hooker
Uppsala Universitet
Emmanuelle Comets's picture
Emmanuelle Comets
UPD
France Mentré's picture
France Mentré
UPD
Marc Lavielle's picture
Marc Lavielle
Inria
Mats Karlsson's picture
Mats Karlsson
Uppsala Universitet
EFPIA
Ivelina Gueorguieva's picture
Ivelina Gueorguieva
Eli Lilly
Marylore Chenel's picture
Marylore Chenel
Institut de Recherches Internationales Servier